{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T11:34:58Z","timestamp":1790854498105,"version":"4.1.0"},"reference-count":58,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,9,12]],"date-time":"2022-09-12T00:00:00Z","timestamp":1662940800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Current coronavirus disease-19 (COVID-19) vaccines are administered by the intramuscular route, but this vaccine administration failed to prevent severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus infection in the upper respiratory tract, mainly due to the absence of virus-specific mucosal immune responses. It is hypothesized that intranasal (IN) vaccination could induce both mucosal and systemic immune responses that blocked SARS-CoV-2 transmission and COVID-19 progression. Here, we evaluated in mice IN administration of three modified vaccinia virus Ankara (MVA)-based vaccine candidates expressing the SARS-CoV-2 spike (S) protein, either the full-length native S or a prefusion-stabilized [S(3P)] protein; SARS-CoV-2-specific immune responses and efficacy were determined after a single IN vaccine application. Results showed that in C57BL\/6 mice, MVA-based vaccine candidates elicited S-specific IgG and IgA antibodies in serum and bronchoalveolar lavages, respectively, and neutralizing antibodies against parental and SARS-CoV-2 variants of concern (VoC), with MVA-S(3P) being the most immunogenic vaccine candidate. IN vaccine administration also induced polyfunctional S-specific Th1-skewed CD4<jats:sup>+<\/jats:sup> and cytotoxic CD8<jats:sup>+<\/jats:sup> T-cell immune responses locally (in lungs and bronchoalveolar lymph nodes) or systemically (in spleen). Remarkably, a single IN vaccine dose protected susceptible K18-hACE2 transgenic mice from morbidity and mortality caused by SARS-CoV-2 infection, with MVA-S(3P) being the most effective candidate. Infectious SARS-CoV-2 viruses were undetectable in lungs and nasal washes, correlating with high titers of S-specific IgGs and neutralizing antibodies against parental SARS-CoV-2 and several VoC. Moreover, low histopathological lung lesions and low levels of pro-inflammatory cytokines in lungs and nasal washes were detected in vaccinated animals. These results demonstrated that a single IN inoculation of our MVA-based vaccine candidates induced potent immune responses, either locally or systemically, and protected animal models from COVID-19. These results also identified an effective vaccine administration route to induce mucosal immunity that should prevent SARS-CoV-2 host-to-host transmission.<\/jats:p>","DOI":"10.3389\/fimmu.2022.995235","type":"journal-article","created":{"date-parts":[[2022,9,12]],"date-time":"2022-09-12T04:40:51Z","timestamp":1662957651000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":30,"title":["Intranasal administration of a single dose of MVA-based vaccine candidates against COVID-19 induced local and systemic immune responses and protects mice from a lethal SARS-CoV-2 infection"],"prefix":"10.3389","volume":"13","author":[{"given":"Patricia","family":"P\u00e9rez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Astorgano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guillermo","family":"Albericio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Flores","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pedro J.","family":"S\u00e1nchez-Cord\u00f3n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanna","family":"Luczkowiak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rafael","family":"Delgado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 M.","family":"Casasnovas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariano","family":"Esteban","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Garc\u00eda-Arriaza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,9,12]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-020-2008-3","article-title":"A new coronavirus associated with human respiratory disease in China","volume":"579","author":"Wu","year":"2020","journal-title":"Nature"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2001017","article-title":"Research t. a novel coronavirus from patients with pneumonia in China, 2019","volume":"382","author":"Zhu","year":"2020","journal-title":"N Engl J Med"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2022.103841","article-title":"Intranasal COVID-19 vaccines: From bench to bed","volume":"76","author":"Alu","year":"2022","journal-title":"EBioMedicine"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2021.109400","article-title":"A single intranasal or intramuscular immunization with chimpanzee adenovirus-vectored SARS-CoV-2 vaccine protects against pneumonia in hamsters","volume":"36","author":"Bricker","year":"2021","journal-title":"Cell Rep"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2017.1377376","article-title":"Immune responses after live attenuated influenza vaccination","volume":"14","author":"Mohn","year":"2018","journal-title":"Hum Vaccin Immunother."},{"key":"B6","doi-asserted-by":"publisher","first-page":"98","DOI":"10.3390\/v9050098.","article-title":"Harnessing local immunity for an effective universal swine influenza vaccine","volume":"9","author":"Tchilian","year":"2017","journal-title":"Viruses"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2021.100230","article-title":"A single intranasal dose of chimpanzee adenovirus-vectored vaccine protects against SARS-CoV-2 infection in rhesus macaques","volume":"2","author":"Hassan","year":"2021","journal-title":"Cell Rep Med"},{"key":"B8","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/j.cell.2020.08.026.","article-title":"Diamond MS. a single-dose intranasal ChAd vaccine protects upper and lower respiratory tracts against SARS-CoV-2","volume":"183","author":"Hassan","year":"2020","journal-title":"Cell"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-020-1070-6","article-title":"Ad26 vaccine protects against SARS-CoV-2 severe clinical disease in hamsters","volume":"26","author":"Tostanoski","year":"2020","journal-title":"Nat Med"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abh0755","article-title":"Intranasal ChAdOx1 nCoV-19\/AZD1222 vaccination reduces viral shedding after SARS-CoV-2 D614G challenge in preclinical models","volume":"13","author":"van Doremalen","year":"2021","journal-title":"Sci Transl Med"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(21)00396-0","article-title":"Safety, tolerability, and immunogenicity of an aerosolised adenovirus type-5 vector-based COVID-19 vaccine (Ad5-nCoV) in adults: Preliminary report of an open-label and randomised phase 1 clinical trial","volume":"21","author":"Wu","year":"2021","journal-title":"Lancet Infect Dis"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1586\/14760584.2013.845531","article-title":"Clinical applications of attenuated MVA poxvirus strain","volume":"12","author":"Gomez","year":"2013","journal-title":"Expert Rev Vaccines"},{"key":"B13","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1016\/bs.aivir.2016.07.001","article-title":"Modified vaccinia virus Ankara: History, value in basic research, and current perspectives for vaccine development","volume":"97","author":"Volz","year":"2017","journal-title":"Adv Virus Res"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2202069119","article-title":"Intranasal inoculation of an MVA-based vaccine induces IgA and protects the respiratory tract of hACE2 mice from SARS-CoV-2 infection","volume":"119","author":"Americo","year":"2022","journal-title":"Proc Natl Acad Sci USA"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.772240","article-title":"Intranasal delivery of MVA vector vaccine induces effective pulmonary immunity against SARS-CoV-2 in rodents","volume":"12","author":"Bosnjak","year":"2021","journal-title":"Front Immunol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.845969","article-title":"MVA-CoV2-S vaccine candidate neutralizes distinct variants of concern and protects against SARS-CoV-2 infection in hamsters","volume":"13","author":"Boudewijns","year":"2022","journal-title":"Front Immunol"},{"key":"B17","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1038\/s41541-022-00436-6","article-title":"Synthetic multiantigen MVA vaccine COH04S1 protects against SARS-CoV-2 in Syrian hamsters and non-human primates","volume":"7","author":"Chiuppesi","year":"2022","journal-title":"NPJ Vaccines"},{"key":"B18","doi-asserted-by":"publisher","first-page":"6121","DOI":"10.1038\/s41467-020-19819-1","article-title":"Development of a multi-antigenic SARS-CoV-2 vaccine candidate using a synthetic poxvirus platform","volume":"11","author":"Chiuppesi","year":"2020","journal-title":"Nat Commun"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.748103","article-title":"The bacterial mucosal immunotherapy MV130 protects against SARS-CoV-2 infection and improves COVID-19 vaccines immunogenicity","volume":"12","author":"Del Fresno","year":"2021","journal-title":"Front Immunol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.02260-20","article-title":"COVID-19 vaccine candidates based on modified vaccinia virus Ankara expressing the SARS-CoV-2 spike induce robust T- and b-cell immune responses and full efficacy in mice","volume":"95","author":"Garcia-Arriaza","year":"2021","journal-title":"J Virol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0257191","article-title":"Vaccinia virus-based vaccines confer protective immunity against SARS-CoV-2 virus in Syrian hamsters","volume":"16","author":"Kulkarni","year":"2021","journal-title":"PloS One"},{"key":"B22","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1038\/s41541-022-00440-w","article-title":"Full efficacy and long-term immunogenicity induced by the SARS-CoV-2 vaccine candidate MVA-CoV2-S in mice","volume":"7","author":"Lazaro-Frias","year":"2022","journal-title":"NPJ Vaccines"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2026785118.","article-title":"One or two injections of MVA-vectored vaccine shields hACE2 transgenic mice from SARS-CoV-2 upper and lower respiratory tract infection","volume":"118","author":"Liu","year":"2021","journal-title":"Proc Natl Acad Sci USA"},{"key":"B24","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1038\/s41541-021-00410-8","article-title":"MVA vector expression of SARS-CoV-2 spike protein and protection of adult Syrian hamsters against SARS-CoV-2 challenge","volume":"6","author":"Meseda","year":"2021","journal-title":"NPJ Vaccines"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.845887","article-title":"Poxvirus MVA expressing SARS-CoV-2 s protein induces robust immunity and protects rhesus macaques from SARS-CoV-2","volume":"13","author":"Mooij","year":"2022","journal-title":"Front Immunol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.824728","article-title":"A single dose of an MVA vaccine expressing a prefusion-stabilized SARS-CoV-2 spike protein neutralizes variants of concern and protects mice from a lethal SARS-CoV-2 infection","volume":"12","author":"Perez","year":"2022","journal-title":"Front Immunol"},{"key":"B27","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1016\/j.immuni.2021.02.001.","article-title":"A modified vaccinia Ankara vector-based vaccine protects macaques from SARS-CoV-2 infection, immune pathology, and dysfunction in the lungs","volume":"54","author":"Routhu","year":"2021","journal-title":"Immunity"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2026207118.","article-title":"Immunogenicity and efficacy of the COVID-19 candidate vector vaccine MVA-SARS-2-S in preclinical vaccination","volume":"118","author":"Tscherne","year":"2021","journal-title":"Proc Natl Acad Sci USA"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1016\/S2666-5247(22)00027-1","article-title":"Safety and immunogenicity of a synthetic multiantigen modified vaccinia virus Ankara-based COVID-19 vaccine (COH04S1): an open-label and randomised, phase 1 trial","volume":"3","author":"Chiuppesi","year":"2022","journal-title":"Lancet Microbe"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1099\/vir.0.81181-0.","article-title":"Recombinant poxviruses as mucosal vaccine vectors","volume":"86","author":"Gherardi","year":"2005","journal-title":"J Gen Virol"},{"key":"B31","first-page":"30","article-title":"[Oral and nasal immunization with poxvirus vacciniae. 3. animal experiments]","volume":"156","author":"Hochstein-Mintzel","year":"1972","journal-title":"Zentralbl Bakteriol Orig B"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.70.9.6418-6424.1996","article-title":"Oral immunization with a replication-deficient recombinant vaccinia virus protects mice against influenza","volume":"70","author":"Bender","year":"1996","journal-title":"J Virol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1016\/s0264-410x(98)00010-3","article-title":"The immunogenicity and efficacy of intranasally or parenterally administered replication-deficient vaccinia-parainfluenza virus type 3 recombinants in rhesus monkeys","volume":"16","author":"Durbin","year":"1998","journal-title":"Vaccine"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1016\/s0264-410x(99)00257-1.","article-title":"Priming and boosting immunity to respiratory syncytial virus by recombinant replication-defective vaccinia virus MVA","volume":"18","author":"Wyatt","year":"1999","journal-title":"Vaccine"},{"key":"B35","article-title":"The smallpox vaccination strain MVA: Marker, genetic structure, experience gained with the parenteral vaccination and behavior in organisms with a debilitated defence mechanism (author\u2019s transl)","volume":"167","author":"Mayr","year":"1978","journal-title":"Zentralbl Bakteriol B"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1128\/jvi.74.2.923-933.2000","article-title":"Biology of attenuated modified vaccinia virus Ankara recombinant vector in mice: Virus fate and activation of b- and T-cell immune responses in comparison with the Western reserve strain and advantages as a vaccine","volume":"4","author":"Ramirez","year":"2000","journal-title":"J Virol"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.2217\/imt-2020-0220","article-title":"Cross-neutralization activity against SARS-CoV-2 is present in currently available intravenous immunoglobulins","volume":"12","author":"Diez","year":"2020","journal-title":"Immunotherapy."},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.25986","article-title":"Evaluation of SARS-CoV-2 neutralizing antibodies using a CPE-based colorimetric live virus micro-neutralization assay in human serum samples","volume":"92","author":"Manenti","year":"2020","journal-title":"J Med Virol"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1009576","article-title":"DC\/L-SIGN recognition of spike glycoprotein promotes SARS-CoV-2 trans-infection and can be inhibited by a glycomimetic antagonist","volume":"17","author":"Thepaut","year":"2021","journal-title":"PloS Pathog"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1373\/clinchem.2012.197863","article-title":"High-yield RNA-extraction method for saliva","volume":"59","author":"Pandit","year":"2013","journal-title":"Clin Chem"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.2807\/1560-7917.ES.2020.25.3.2000045","article-title":"Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR","volume":"25","author":"Corman","year":"2020","journal-title":"Euro Surveill"},{"key":"B42","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1016\/j.chom.2020.05.020.","article-title":"A mouse model of SARS-CoV-2 infection and pathogenesis","volume":"28","author":"Sun","year":"2020","journal-title":"Cell Host Microbe"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0012395","article-title":"Immunogenic profiling in mice of a HIV\/AIDS vaccine candidate (MVA-b) expressing four HIV-1 antigens and potentiation by specific gene deletions","volume":"5","author":"Garcia-Arriaza","year":"2010","journal-title":"PloS One"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.4269\/ajtmh.20-0762","article-title":"Evaluation of K18-hACE2 mice as a model of SARS-CoV-2 infection","volume":"103","author":"Moreau","year":"2020","journal-title":"Am J Trop Med Hyg"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1038\/s41590-020-0778-2","article-title":"SARS-CoV-2 infection of human ACE2-transgenic mice causes severe lung inflammation and impaired function","volume":"21","author":"Winkler","year":"2020","journal-title":"Nat Immunol"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-020-2196-x","article-title":"Virological assessment of hospitalized patients with COVID-2019","volume":"581","author":"Wolfel","year":"2020","journal-title":"Nature"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1038\/srep32973","article-title":"Sterilizing immunity to influenza virus infection requires local antigen-specific T cell response in the lungs","volume":"6","author":"Dutta","year":"2016","journal-title":"Sci Rep"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.3390\/v14020187.","article-title":"Mucosal vaccines, sterilizing immunity, and the future of SARS-CoV-2 virulence","volume":"14","author":"Focosi","year":"2022","journal-title":"Viruses"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1086\/656188","article-title":"Multiple infections with seasonal influenza a virus induce cross-protective immunity against A(H1N1) pandemic influenza virus in a ferret model","volume":"202","author":"Laurie","year":"2010","journal-title":"J Infect Dis"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0705191105","article-title":"Aerosol immunization with NYVAC and MVA vectored vaccines is safe, simple, and immunogenic","volume":"105","author":"Corbett","year":"2008","journal-title":"Proc Natl Acad Sci USA"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1128\/CVI.00690-12","article-title":"Evaluation of the safety and immunogenicity of a candidate tuberculosis vaccine, MVA85A, delivered by aerosol to the lungs of macaques","volume":"20","author":"White","year":"2013","journal-title":"Clin Vaccine Immunol"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1002790","article-title":"Alternate aerosol and systemic immunisation with a recombinant viral vector for tuberculosis, MVA85A: A phase I randomised controlled trial","volume":"16","author":"Manjaly Thomas","year":"2019","journal-title":"PloS Med"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1099\/vir.0.81579-0.","article-title":"Comparative evaluation of two severe acute respiratory syndrome (SARS) vaccine candidates in mice challenged with SARS coronavirus","volume":"87","author":"See","year":"2006","journal-title":"J Gen Virol"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abd2223","article-title":"IgA dominates the early neutralizing antibody response to SARS-CoV-2","volume":"13","author":"Sterlin","year":"2021","journal-title":"Sci Transl Med"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abf1555","article-title":"Enhanced SARS-CoV-2 neutralization by dimeric IgA","volume":"13","author":"Wang","year":"2021","journal-title":"Sci Transl Med"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1038\/nm1213","article-title":"Mucosal immunity and vaccines","volume":"11","author":"Holmgren","year":"2005","journal-title":"Nat Med"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2021.121180","article-title":"Intranasal vaccine: Factors to consider in research and development","volume":"609","author":"Xua","year":"2021","journal-title":"Int J Pharm"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1099\/vir.0.83018-0.","article-title":"Virus distribution of the attenuated MVA and NYVAC poxvirus strains in mice","volume":"88","author":"G\u00f3mez","year":"2007","journal-title":"J Gen Virol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.995235\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,12]],"date-time":"2022-09-12T04:40:56Z","timestamp":1662957656000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.995235\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,12]]},"references-count":58,"alternative-id":["10.3389\/fimmu.2022.995235"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2022.995235","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,12]]},"article-number":"995235"}}